Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-06-24 EDT			5-day change	1st Jan Change
362.40 ^DKK	-1.68%		-3.90%	-49.35%

06-19	Zealand Pharma A/S(CPSE:ZEAL) dropped from OMX Nordic 40 Index	CI
06-18	Zealand Pharma Announces Positive Results From 28-Week Phase 1B Dapiglutide Trial	RE

Zealand Pharma A/S, 2023 Earnings Call, Feb 27, 2024

Published on 2024-02-27 at 08:00

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the Zealand Pharma Results for Full Year 2023 Webcast. [Operator Instructions] Please be advised

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Zealand Pharma A/S

Zealand Pharma A/S(CPSE:ZEAL) dropped from OMX Nordic 40 Index	06-19	CI
Zealand Pharma Announces Positive Results From 28-Week Phase 1B Dapiglutide Trial	06-18	RE
Zealand Pharma A/S Announces Positive Topline Clinical Results from Part 2 of a Phase 1b Multiple Ascending Dose Trial	06-18	CI
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	06-13	RE
Zealand Pharma A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 04:00 PM	06-11
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial	06-10	RE
Zealand Pharma A/S Submits Marketing Authorization Application to the European Medicines Agency for Glepaglutide in Short Bowel Syndrome	06-02	CI
Zealand Pharma Files EU Marketing Authorization Application for Short Bowel Syndrome Treatment	06-02	MT
Zealand Pharma Applies To EMA For Marketing Authorization For Glepaglutide In Short Bowel Syndrome	06-02	RE
European stocks recover after Trump delays EU tariffs in hopes of deal	05-26	RE
Danish Biotech Zealand Pharma Names Chief Development Officer	05-20	MT
Zealand Pharma A/S Appoints Steven Johnson as Chief Development Officer	05-19	CI
Deutsche Bank lowers its target price for Zealand Pharma to 485 Danish kroner (750), reiterates hold	05-19	FW
Weight-loss drug developers line up to tap lucrative market as competition heats up	05-16	RE
Denmark says Trump's drug pricing order is a step in the wrong direction	05-16	RE
Zealand Pharma A/S Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08:00 AM	05-14
Zealand Pharma A/S Announces Closing of Collaboration and License Agreement with Roche	05-09	CI
DNB lowers target price for Zealand Pharma to DKK 950 (1,000), reiterates buy recommendation - BN	05-09	FW
Zealand Pharma-Roche Deal for Obesity Drug Candidate Takes Effect	05-09	MT
Goldman Sachs lowers target price for Zealand Pharma to DKK 806 (USD 873), reiterates buy rating - BN	05-09	FW
SEB lowers target price for Zealand Pharma to DKK 780 (850), reiterates buy recommendation - BN	05-09	FW
Zealand Pharma A/S, Q1 2025 Earnings Call, May 08, 2025	05-08
Zealand Pharma Keeps Guidance For 2025 Unchanged	05-08	RE
Zealand Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2025	05-07	CI
Kempen Lowers Zealand Pharma PT, Keeps at Buy	05-05	MT